Equity Research Database

Institutional Investment Pitches

Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.

Home Letters Funds Account

Aristotle Core Equity Fund's investment thesis on Boston Scientific Corporation ($BSX) — Q2 2026 | Buyside Digest

All Pitches

View Letter Analysis

$BSXNYSEBoston Scientific Corporation

BULL

Aristotle Core Equity Fund—BSX

Fund Letter

Q2 2026

Published August 10, 2026

View Fund Profile

$49.51USD

+3.6% vs last month

$51.83Pitched

-4.5% since pitch

Market Cap$71.7B

P/E (TTM)N/A

52-Wk RangeN/A

Div. YieldN/A

Technical Chart

From the Fund Letter

The Aristotle Core Equity Fund returned 14.69% in Q2 2026, slightly underperforming the S&P 500's 15.20% return due to allocation effects. The quarter was...

— Mr. Fitzpatrick

BSD Research Exclusive

Unlock Full Institutional Investment Theses

Full equity research memos, financial breakdowns, and hedge fund thesis write-ups are reserved for BSD Research ($55/mo) and Pro subscribers.

6,000+ Institutional Pitches

Proprietary AI Analysis

100 Letter Unlocks/Cycle

SUBSCRIBE TO BSD RESEARCH ($55/MO)Compare All Plans

Already a Research or Pro subscriber? Sign In

◆ Keep Reading

What other investors think about $BSX, and what else Aristotle Core Equity Fund is buying.

Other pitches on $BSX

Other investors who've written on Boston Scientific Corporation

Edgewood ManagementBULL

Pitched Sep 30, 2025

A highly innovative pipeline in cardiology and other medtech spaces continues to fuel double-digit revenue growth and operating leverage. Recent stock declines...

View all $BSX pitches →